强一股份今日开启申购，公司本次发行前总股本为9716.94万股，本次拟公开发行股票3238.99万股，占 发行后总股本的比例为25.00%，其中网上发行777.35万股，申购代码787809，申购价格为85.09元 ，发 行市盈率为48.55倍，单一账户申购上限为0.75万股，申购数量为500股的整数倍，顶格申购需持有沪市 市值7.50万元。 公司具备探针卡及其核心部件的专业设计能力，是境内极少数拥有自主MEMS探针制造技术并能够批量 生产、销售MEMS探针卡的厂商。 项目投资金额(万元) 南通探针卡研发及生产项目 120000.00 苏州总部及研发中心建设项目 30000.00 主要财务指标 股票代码 688809 股票简称 强一股份 申购代码 787809 发行价(元) 85.09 发行市盈率(倍) 48.55 参考行业市盈率 57.92 申购日期 2025.12.19 网上发行数量(万股) 777.35 总发行数量(万股) 3238.99 申购股数上限(万股) 0.75 顶格申购需配市值(万元) 7.50 中签号公布及缴款日 2025.12.23 公司募集资金投向 财务指标/时间2024年2023年20 ...

Core Viewpoint - The article highlights the competitive nature of the offline subscription for Muxi Co., with significant interest from institutional investors, indicating a strong demand for shares in the technology sector [1][2]. Group 1: Subscription and Allocation Details - Muxi Co. had a total of 401 million shares issued at a price of 104.66 yuan per share, raising approximately 4.197 billion yuan, with a total offline subscription amounting to 571.69 million shares [1]. - The offline allocation structure shows that 269 institutional investors participated, with public funds, insurance asset management, and securities asset management dominating the allocation [3][4]. - A total of 85.83% of the offline subscription volume came from A-class investors, who received 98.04% of the total offline allocation, indicating a strong preference for long-term holding [3][4]. Group 2: Institutional Participation - Major public funds accounted for over half of the total allocation, with 94 public funds participating and receiving 1.339 million shares, amounting to approximately 1.402 billion yuan [4][5]. - Notable public funds such as E Fund, Southern Fund, and ICBC Credit Suisse were among the top participants, with significant allocations [4][5][6]. - Insurance funds also played a crucial role, collectively acquiring about 404.70 million shares, with an average of 5,000 shares per product, indicating a strategic long-term investment approach [7][8]. Group 3: Private Fund Participation - Private funds, particularly quantitative funds, adopted a strategy of broad participation with smaller allocations, resulting in limited but widespread involvement [10][12]. - A total of 110 private funds participated, acquiring approximately 367,500 shares, which accounted for a small portion of the total allocation [12][13]. - The article notes a trend where larger private funds dominate the allocation, while smaller funds tend to participate in a more fragmented manner [12][13]. Group 4: Market Implications - The allocation structure reflects a growing trend in the technology IPO market, where long-term institutional investors are complemented by more agile private funds, creating a balanced investment ecosystem [13]. - The combination of long-term capital from public and insurance funds with the liquidity provided by private funds is seen as a stabilizing factor for stock prices post-IPO [9][13].

优迅股份今日开启申购，公司本次发行前总股本为6000.00万股，本次拟公开发行股票2000.00万股，占 发行后总股本的比例为25.00%，其中网上发行480.00万股，申购代码787807，申购价格为51.66元 ，发 行市盈率为60.27倍，单一账户申购上限为0.45万股，申购数量为500股的整数倍，顶格申购需持有沪市 市值4.50万元。 公司作为国内光通信领域的"国家级制造业单项冠军企业"，专注于光通信前端收发电芯片的研发、设计 与销售。（数据宝） 新股申购信息 | 股票代码 | 688807 | 股票简称 | 优迅股份 | | --- | --- | --- | --- | | 申购代码 | 787807 | 发行价（元） | 51.66 | | 发行市盈率（倍） | 60.27 | 参考行业市盈率 | 58.09 | | 申购日期 | 2025.12.08 | 网上发行数量（万股） | 480.00 | | 总发行数量（万股） | 2000.00 | 申购股数上限（万股） | 0.45 | | 顶格申购需配市值（万元） | 4.50 | 中签号公布及缴款日 | 2025.12.10 | 公司募集资金 ...

Company Overview - Angrui Microelectronics is set to launch its public offering, with a total share capital of 74.6488 million shares before the issuance, and plans to issue 24.8829 million shares, representing 25.00% of the post-issue total share capital [1] - The company specializes in the research, design, and sales of RF front-end chips, RF SoC chips, and other analog chips [1] IPO Details - The subscription code for the public offering is 787790, with a subscription price of 83.06 yuan per share [1] - The online issuance will consist of 3.9810 million shares, and the maximum subscription limit for a single account is 0.35 million shares, requiring a minimum market value of 35,000 yuan in the Shanghai market for the highest subscription [1] Fundraising Allocation - The company plans to allocate funds as follows: - 1.0961225 billion yuan for the R&D and industrialization upgrade of 5G RF front-end chips and modules - 408 million yuan for the R&D and industrialization upgrade of RF SoC - 563.1707 million yuan for the construction of the headquarters and R&D center [1] Financial Performance - Key financial indicators for the company are as follows: - Total assets for 2024 are projected at 1.7212036 billion yuan, up from 1.7141510 billion yuan in 2023 - Net assets are expected to decrease to 977.2571 million yuan in 2024 from 1.0400325 billion yuan in 2023 - Operating revenue is forecasted to rise to 2.1013197 billion yuan in 2024, compared to 1.6948705 billion yuan in 2023 - The net profit attributable to shareholders is projected to be -64.7092 million yuan in 2024, an improvement from -450.1332 million yuan in 2023 - Basic and diluted earnings per share are both expected to be -0.8700 yuan in 2024, improving from -6.0300 yuan in 2023 - The weighted average return on equity is projected at -6.42% for 2024, an improvement from -43.16% in 2023 - Net cash flow from operating activities is expected to be -186.7206 million yuan in 2024, worsening from -67.0907 million yuan in 2023 - R&D investment is projected at 313.8440 million yuan in 2024, down from 396.3284 million yuan in 2023, with R&D investment as a percentage of operating revenue at 14.94% in 2024, down from 23.38% in 2023 [1]

Group 1 - The company Anruiwei is set to launch its public offering, with a total share capital of 74.6488 million shares before the issuance and plans to issue 24.8829 million shares, representing 25% of the post-issue total share capital [1] - The subscription price is set at 83.06 yuan per share, with a maximum subscription limit of 3,500 yuan in market value required for top-tier subscriptions [1] - The company specializes in the research, design, and sales of RF front-end chips, RF SoC chips, and other analog chips [1] Group 2 - The company aims to raise funds for three main projects: 1) 5G RF front-end chip and module R&D and industrial upgrade project (109,612.25 million yuan), 2) RF SoC R&D and industrial upgrade project (40,800.82 million yuan), and 3) Headquarters and R&D center construction project (56,317.07 million yuan) [1] - Key financial indicators for 2024 show total assets of 1,721,203.6 million yuan, net assets of 977,257.1 million yuan, and operating income of 2,101,319.7 million yuan [2] - The company reported a net profit attributable to shareholders of the parent company of -6,470.92 million yuan for 2024, with a basic and diluted earnings per share of -0.87 yuan [2] Group 3 - To participate in the Sci-Tech Innovation Board IPOs, individual investors must meet specific criteria, including maintaining an average asset of at least 500,000 yuan in their securities and funds accounts for the past 20 trading days [3] - Investors must have been engaged in securities trading for over 24 months and hold a minimum market value of 10,000 yuan in Shanghai-listed stocks [3] - The subscription process allows for a maximum of one subscription unit (500 shares) for every 5,000 yuan in market value, with the total subscription not exceeding one-thousandth of the initial public offering amount [3]

Summary of Key Points Core Viewpoint - The company Bai'ao Saitou is set to launch its public offering, with a total share capital of 399 million shares before the issuance and plans to issue 47.5 million shares, representing 10.63% of the post-issue total share capital. The offering price is set at 26.68 yuan per share, with a high price-to-earnings ratio of 519.12 times, indicating a premium valuation compared to the industry average of 39.31 times [1]. Company Information - Bai'ao Saitou specializes in providing innovative model animals and preclinical pharmaceutical research and development services based on its self-developed gene editing technology [1]. New Share Issuance Details - The public offering will consist of 47.5 million shares, with 7.6 million shares available for online subscription. The subscription code is 787796, and the maximum subscription limit for a single account is 7,500 shares, requiring a minimum market value of 75,000 yuan in the Shanghai market [1]. Fundraising Allocation - The funds raised from the public offering will be allocated to several projects: - Early drug research and development service platform construction: 59.797 million yuan - Antibody drug research and evaluation project: 39.513 million yuan - Preclinical and clinical research projects: 40 million yuan - Supplementing working capital: 50 million yuan [1]. Financial Performance - The company reported total assets of 2.415 billion yuan in 2024, a decrease from 2.449 billion yuan in 2023 and 2.799 billion yuan in 2022. - Net assets increased to 834.0588 million yuan in 2024 from 785.8889 million yuan in 2023, but down from 1.1462665 billion yuan in 2022. - Operating revenue rose to 980.4539 million yuan in 2024, compared to 716.9118 million yuan in 2023 and 533.8808 million yuan in 2022. - The net profit attributable to shareholders was 33.5418 million yuan in 2024, a significant recovery from losses of 38.295 million yuan in 2023 and 60.1947 million yuan in 2022 [2]. Research and Development Investment - Research and development investment amounted to 323.9245 million yuan in 2024, accounting for 33.04% of operating revenue, a decrease from 66.17% in 2023 and 130.96% in 2022 [2].

据悉，A类投资者包括公募、社保基金、养老金、年金基金、银行理财产品、保险资金、保险资产管理产品和合格境外投资者资金。B类投资者是上述之 外的其他投资者，比如私募、券商资管、券商自营等。 B类投资者获配份额大幅减少 网下打新或将迎来新局面。 11月25日晚间，摩尔线程公布了网下初步配售结果。结果显示，A类投资者获配数量占比98.44%，B类投资者获配仅占比1.56%。从具体的获配股数来 看，有的B类投资者最少只获配了39股。记者获悉，这是科创成长层优化发行承销制度的结果，对于网下打新，实行的是约定限售方式。 根据公告，本次配售需满足限售比例更高、限售期更长的网下投资者配售比例应当不低于其他投资者的要求。A1类投资者（选择档位一的A类投资者）的 配售比例不低于A2类投资者（选择档位二的A类投资者）的3倍，同时A2类投资者的配售比例不低于A3类（选择档位三的A类投资者）与B类投资者的3 倍。 也就是说，A1类投资者的获配比例，至少要是B类投资者获配比例的9倍。规则有意拉大了新股的获配比例。从摩尔线程实际申购结果来看，A类投资者 主要选择的是档位一，因为获配比例更高。A1类投资者的获配比例为0.07%，B类投资者的获 ...

Company Overview - Hengkun New Materials is set to begin subscription tomorrow, with a total share capital of 382 million shares before the issuance and plans to publicly issue 67.3979 million shares, accounting for 15.00% of the total share capital post-issuance [1] - The subscription price is set at 14.99 yuan, with an issuance price-to-earnings ratio of 71.42 times, compared to the industry average of 60.47 times [1] - The company’s products are essential materials for integrated circuit wafer manufacturing, primarily used in advanced NAND, DRAM storage chips, and logic chips at 90nm technology nodes and below [1] Subscription Details - The subscription code is 787727, with an online issuance of 10.7835 million shares and a maximum subscription limit of 10,500 shares per account [1] - The subscription date is November 7, 2025, with the announcement of the winning numbers and payment date on November 11, 2025 [1] Financial Highlights - Total assets for 2024 are reported at 2.645 billion yuan, an increase from 2.091 billion yuan in 2023 and 1.633 billion yuan in 2022 [1] - Net assets have grown to 1.500 billion yuan in 2024 from 1.382 billion yuan in 2023 and 1.273 billion yuan in 2022 [1] - Operating revenue for 2024 is 547.9388 million yuan, up from 367.7078 million yuan in 2023 and 321.7652 million yuan in 2022 [1] - The net profit attributable to shareholders for 2024 is 96.9192 million yuan, compared to 89.8493 million yuan in 2023 and 100.9030 million yuan in 2022 [1] - Research and development investment for 2024 is 88.6085 million yuan, representing 16.17% of operating revenue, an increase from 14.59% in 2023 and 13.28% in 2022 [1] Fundraising Allocation - The company plans to allocate 399.8022 million yuan to the second phase of the integrated circuit precursor project and 606.8928 million yuan to the advanced materials project for integrated circuits [1]

Core Viewpoint - Hengkun New Materials has initiated its public offering, with a total share capital of 382 million shares before the issuance, and plans to issue 67.4 million shares, accounting for 15% of the post-issue total share capital [1] Group 1: IPO Details - The public offering price is set at 14.99 yuan per share, with an issuance price-to-earnings ratio of 71.42 times, compared to the industry average of 60.47 times [1] - The maximum subscription limit for a single account is 10,500 shares, with subscriptions required to be in multiples of 500 shares [1] - The online subscription date is November 7, 2025, with the announcement of the winning numbers and payment date on November 11, 2025 [1] Group 2: Company Products and Applications - The company's products are primarily used in the production processes of advanced NAND and DRAM storage chips, as well as logic chips at 90nm technology nodes and below, including lithography and thin film deposition [1] Group 3: Fundraising Allocation - The company plans to allocate 399.8 million yuan to the second phase of the integrated circuit precursor project and 606.9 million yuan to the advanced materials project for integrated circuits [1] Group 4: Financial Performance - Total assets for 2024 are projected at 2.645 billion yuan, an increase from 2.091 billion yuan in 2023 and 1.633 billion yuan in 2022 [2] - Net assets are expected to reach 1.501 billion yuan in 2024, up from 1.382 billion yuan in 2023 and 1.273 billion yuan in 2022 [2] - Operating revenue is forecasted at 547.9 million yuan for 2024, compared to 367.7 million yuan in 2023 and 321.8 million yuan in 2022 [2] - The net profit attributable to shareholders is projected at 96.9 million yuan for 2024, slightly up from 89.8 million yuan in 2023 but down from 100.9 million yuan in 2022 [2] - Research and development investment is expected to be 88.6 million yuan in 2024, representing 16.17% of operating revenue [2]

Core Viewpoint - The company, Bibet, is set to launch its public offering with a total share capital of 360 million shares, aiming to issue 90 million shares, which represents 20% of the post-issue total share capital, at a price of 17.78 yuan per share [1] Company Overview - Bibet focuses on the treatment of major diseases such as tumors, autoimmune diseases, and metabolic diseases, with core products classified as Class 1 new chemical drugs [1] - The main therapeutic areas include malignant lymphoma, breast cancer, non-small cell lung cancer, ovarian cancer, psoriasis, and diabetes-related non-alcoholic fatty liver disease [1] Public Offering Details - The public offering will consist of 90 million shares, with 14.4 million shares available for online subscription [1] - The subscription code is 787759, and the maximum subscription limit for a single account is 14,000 shares, requiring a market value of 140,000 yuan in the Shanghai market for the highest subscription [1] - The announcement of the winning numbers and payment date is set for October 21, 2025 [1] Fundraising Allocation - The funds raised will be allocated as follows: - New drug research and development project: 94,912.34 thousand yuan - Construction of the Qingyuan R&D center and formulation industrialization base: 55,548.57 thousand yuan - Supplementing working capital: 50,000.00 thousand yuan [1] Financial Performance - The company reported total assets of 33,247.71 thousand yuan in 2024, down from 44,187.25 thousand yuan in 2023 and 58,721.68 thousand yuan in 2022 [2] - Net assets decreased to 29,022.01 thousand yuan in 2024 from 31,811.96 thousand yuan in 2023 and 46,833.49 thousand yuan in 2022 [2] - The company has not generated any operating revenue, with a net loss attributable to shareholders of 5,599.83 thousand yuan in 2024, an improvement from a loss of 17,275.51 thousand yuan in 2023 and 18,833.88 thousand yuan in 2022 [2] - Research and development expenses were 12,028.74 thousand yuan in 2024, down from 15,765.12 thousand yuan in 2023 and 16,674.07 thousand yuan in 2022 [2]